Drug development for neurodegenerative diseases is struggling with one of its most intractable barriers: the slow, variable, and subjective nature of clinical endpoints Traditional assessment scales, ...
Roger Johansson was funded by the Swedish Research Council grant no. 2015-01206 Mikael Johansson was funded by the Marcus and Amalia Wallenberg Foundation award MAW2015.0043. It could help research in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results